IDEAS home Printed from https://ideas.repec.org/a/cup/hecopl/v7y2012i04p393-409_00.html
   My bibliography  Save this article

Evidence and values: paying for end-of-life drugs in the British NHS

Author

Listed:
  • Chalkidou, Kalipso

Abstract

In January 2009, Britain's National Institute for Health and Clinical Excellence (NICE), following a very public debate triggered by its decision, six months earlier, provisionally to rule against the adoption by the National Health Service (NHS) of an expensive drug for advanced renal cancer, introduced a new policy for evaluating pharmaceuticals for patients nearing the end of their lives. NICE's so-called end-of-life (EOL) guidance for its Committees effectively advises them to deviate from the Institute's threshold range and to value the lives of (mostly) dying cancer patients more than the lives of those suffering from other, potentially curable, chronic or acute conditions. This article tells the story of the EOL guidance. Through looking at specific EOL decisions between 2009 and 2011 and the reactions by stakeholders to these decisions and the policy itself, it discusses the triggers for NICE's EOL guidance, the challenges NICE faces in implementing it and the policy's putative implications for the future role of NICE in the NHS, especially in the context of value-based reforms in the pricing and evaluation of pharmaceuticals, currently under consideration.

Suggested Citation

  • Chalkidou, Kalipso, 2012. "Evidence and values: paying for end-of-life drugs in the British NHS," Health Economics, Policy and Law, Cambridge University Press, vol. 7(4), pages 393-409, October.
    • Handle: RePEc:cup:hecopl:v:7:y:2012:i:04:p:393-409_00
    as

    Download full text from publisher

    File URL: https://www.cambridge.org/core/product/identifier/S1744133112000205/type/journal_article
    File Function: link to article abstract page
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mason, Helen & van Exel, Job & Baker, Rachel & Brouwer, Werner & Donaldson, Cam, 2016. "From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries," Social Science & Medicine, Elsevier, vol. 166(C), pages 205-213.
    2. Lancsar, Emily & Gu, Yuanyuan & Gyrd-Hansen, Dorte & Butler, Jim & Ratcliffe, Julie & Bulfone, Liliana & Donaldson, Cam, 2020. "The relative value of different QALY types," Journal of Health Economics, Elsevier, vol. 70(C).
    3. Bae, Eun-Young & Lim, Min Kyoung & Lee, Boram & Bae, Green, 2020. "Who should be given priority for public funding?," Health Policy, Elsevier, vol. 124(10), pages 1108-1114.
    4. Hansen, Lise Desireé & Kjær, Trine, 2019. "Disentangling public preferences for health gains at end-of-life: Further evidence of no support of an end-of-life premium," Social Science & Medicine, Elsevier, vol. 236(C), pages 1-1.
    5. Bae, Eun-Young & Lim, Min Kyoung & Lee, Boram & Bae, Green & Hong, Jihyung, 2023. "Public preferences in healthcare resource allocation: A discrete choice experiment in South Korea," Health Policy, Elsevier, vol. 138(C).
    6. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    7. Baker, Rachel & Mason, Helen & McHugh, Neil & Donaldson, Cam, 2021. "Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices," Social Science & Medicine, Elsevier, vol. 277(C).
    8. Stenmarck, Mille Sofie & Whitehurst, David GT. & Baker, Rachel & Barra, Mathias, 2024. "Charting public views on the meaning of illness severity," Social Science & Medicine, Elsevier, vol. 347(C).
    9. Dorte Gyrd‐Hansen, 2018. "Is there additional value attached to health gains at the end of life? A revisit," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 71-75, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cup:hecopl:v:7:y:2012:i:04:p:393-409_00. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Kirk Stebbing (email available below). General contact details of provider: https://www.cambridge.org/hep .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.